AGF Management Ltd. decreased its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 41.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 86,660 shares of the medical research company's stock after selling 60,774 shares during the quarter. AGF Management Ltd.'s holdings in Amgen were worth $22,587,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new stake in Amgen during the 3rd quarter valued at about $25,000. Centricity Wealth Management LLC bought a new position in shares of Amgen in the fourth quarter worth approximately $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the third quarter valued at approximately $29,000. Synergy Investment Management LLC bought a new stake in shares of Amgen during the fourth quarter valued at approximately $34,000. Finally, Heck Capital Advisors LLC purchased a new position in Amgen in the 4th quarter worth approximately $36,000. Hedge funds and other institutional investors own 76.50% of the company's stock.
In related news, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares of the company's stock, valued at $11,240,533.68. The trade was a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is currently owned by insiders.
AMGN traded down $6.39 on Wednesday, hitting $312.50. 3,181,700 shares of the company's stock traded hands, compared to its average volume of 2,561,200. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company's 50 day simple moving average is $288.66 and its 200-day simple moving average is $299.43. The firm has a market cap of $167.88 billion, a price-to-earnings ratio of 41.39, a P/E/G ratio of 2.63 and a beta of 0.53.
Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.05%. Amgen's dividend payout ratio (DPR) is 126.09%.
Several analysts have commented on the company. Royal Bank of Canada reiterated an "outperform" rating and set a $324.00 target price on shares of Amgen in a research note on Friday, January 24th. William Blair reiterated an "outperform" rating on shares of Amgen in a report on Tuesday, November 12th. StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Wolfe Research initiated coverage on shares of Amgen in a report on Friday, November 15th. They set a "peer perform" rating on the stock. Finally, Wells Fargo & Company reissued an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $314.04.
Read Our Latest Report on Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.